INVENTISBIO CO., LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.79 CNY | -2.20% |
|
+0.31% | -35.34% |
Valuation
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Capitalization 1 | 7,636 | 8,706 | 5,645 | - | - |
| Enterprise Value (EV) 1 | 7,636 | 8,706 | 5,645 | 5,645 | 5,645 |
| P/E ratio | -14 x | -30.7 x | -19.6 x | -18.6 x | -81.6 x |
| Yield | - | - | - | - | - |
| Capitalization / Revenue | - | 46.9 x | 43.7 x | 17.6 x | 12.6 x |
| EV / Revenue | - | 46.9 x | 43.7 x | 17.6 x | 12.6 x |
| EV / EBITDA | - | -31.8 x | -18 x | -28.3 x | -64.9 x |
| EV / FCF | - | -27.7 x | -23.8 x | -14.2 x | -21.3 x |
| FCF Yield | - | -3.61% | -4.2% | -7.03% | -4.69% |
| Price to Book | - | 4.36 x | 2.85 x | 2.88 x | 3.52 x |
| Nbr of stocks (in thousands) | 575,000 | 575,000 | 576,659 | - | - |
| Reference price 2 | 13.28 | 15.14 | 9.790 | 9.790 | 9.790 |
| Announcement Date | 2/27/23 | 2/6/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net sales 1 | - | 185.5 | 129.2 | 320 | 447.5 |
| EBITDA 1 | - | -273.8 | -314 | -199.7 | -87 |
| EBIT 1 | - | -284 | -288 | -186.9 | -66 |
| Operating Margin | - | -153.06% | -222.91% | -58.39% | -14.75% |
| Earnings before Tax (EBT) 1 | - | -284 | -288 | -186.9 | -67 |
| Net income 1 | -483.5 | -284 | -288 | -183.4 | -67 |
| Net margin | - | -153.06% | -222.91% | -57.32% | -14.97% |
| EPS 2 | -0.9500 | -0.4939 | -0.5000 | -0.5267 | -0.1200 |
| Free Cash Flow 1 | - | -314 | -237.2 | -397.1 | -264.9 |
| FCF margin | - | -169.27% | -183.59% | -124.1% | -59.2% |
| FCF Conversion (EBITDA) | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - |
| Announcement Date | 2/27/23 | 2/6/24 | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - |
| Net Cash position | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - |
| Free Cash Flow 1 | - | -314 | -237 | -397 | -265 |
| ROE (net income / shareholders' equity) | - | -13.5% | -21.2% | -12% | -4.2% |
| ROA (Net income/ Total Assets) | - | -13.3% | -15.3% | -12.9% | -3.5% |
| Assets 1 | - | 2,135 | 1,882 | 1,418 | 1,914 |
| Book Value Per Share 2 | - | 3.470 | 3.440 | 3.400 | 2.780 |
| Cash Flow per Share 2 | - | -0.5400 | -0.7400 | -0.3200 | - |
| Capex 1 | - | 6.29 | 9.3 | 13.2 | 60.3 |
| Capex / Sales | - | 3.39% | 7.2% | 4.11% | 13.47% |
| Announcement Date | 2/27/23 | 2/6/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
9.79
CNY
Average target price
18.5
CNY
Spread / Average Target
+88.97%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -35.34% | 781M | |
| +2.93% | 108B | |
| +8.82% | 105B | |
| +1.46% | 23.46B | |
| -14.60% | 21.72B | |
| -7.05% | 18.64B | |
| -38.55% | 17.45B | |
| -8.83% | 17.19B | |
| +5.51% | 13.99B | |
| +37.49% | 12.53B |
- Stock Market
- Equities
- 688382 Stock
- Financials InventisBio Co., Limited